The Motivator: Summer/Fall 2010
By Diana M. Schneider, PhD and Jack Burks, MD
A comprehensive overview of the eight FDA-approved disease-modifying therapies used to slow MS activity (including the newly approved oral therapy, Gilenya), and initial findings on many of the experimental treatments in development for the treatment of MS.
By Douglas G. Franklin
MSAA's president and CEO talks about some of the successful fundraising events held this year by dedicated and supportive volunteers.
By Jack Burks, MD
MSAA's chief medical officer answers questions sent in by readers.
By Robert Rapp and Peter Damiri
From MSA to MSAA, milestones from our 40 years of service are highlighted.
By Neal Zoren
In this issue's column, we let donors know more about the fundraising process and the importance of their contributions. MSAA's fundraising program, "Swim for MS," and charitable IRA rollovers are also described
By Barbara Ellis
One of our readers writes about her special dream to "Let Go and Fly," along with her exciting lifestyle changes after being diagnosed with MS.
Three informative books from MSAA's Lending Library are featured.